Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex, Bextra To Be Targets Of Public Citizen Withdrawal Petition

This article was originally published in The Pink Sheet Daily

Executive Summary

The watchdog group plans to file a petition in the next week calling for the withdrawal of Pfizer's COX-2 inhibitors. Celebrex and Bextra are among 180 currently marketed drugs Public Citizen advises consumers "do not use" on its expanded worstpills.org website.

You may also be interested in...



Pfizer's Celebrex, Bextra Targets Of Public Citizen Withdrawal Petition

Public Citizen tells FDA that COX-2 inhibitors have inherent cardiovascular risks and offer no efficacy advantages over non-selective NSAIDs. The group suggests the mechanism that creates the COX-2 inhibitors' thrombogenicity is "increased platelet-vessel wall interactions and firm adhesions."

Pfizer's Celebrex, Bextra Targets Of Public Citizen Withdrawal Petition

Public Citizen tells FDA that COX-2 inhibitors have inherent cardiovascular risks and offer no efficacy advantages over non-selective NSAIDs. The group suggests the mechanism that creates the COX-2 inhibitors' thrombogenicity is "increased platelet-vessel wall interactions and firm adhesions."

FDA Drug Safety Initiative Will Include New Website On Rx Risks

The site is intended as an avenue for the agency to disclose safety issues that have not yet been definitively reviewed, and to emphasize the risks with all prescription drugs. The website proposal is understood to be in the internal agency review phase.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel